Evidence map›Paper›PMID 40548349›Full record

ArticleFrontiers in molecular biosciences2025

Mitochondrial mass and mitochondrial membrane potential of peripheral lymphocytes: promising biomarkers of systemic lupus erythematosus.

Guanfei Zhao, Haolong Li, Yutong Miao, Linlin Cheng, Yuying Chen, Yuan Huang, Hongyun Zhao, Yongmei Liu, Yipei Jing, Shasha Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Guanfei Zhao *Department of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Haolong Li *Department of Clinical Laboratory, State key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Yutong MiaoDepartment of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Linlin ChengDepartment of Clinical Laboratory, State key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Yuying ChenDepartment of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Yuan HuangDepartment of Clinical Laboratory, State key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Hongyun ZhaoDepartment of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Yongmei LiuDepartment of Clinical Laboratory, State key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Yipei JingDepartment of Clinical Laboratory, State key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Shasha WangDepartment of Clinical Laboratory, State key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Yongzhe LiDepartment of Clinical Laboratory, State key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Rui ZhangDepartment of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mitochondrial dysfunction is implicated in the pathogenesis of systemic lupus erythematosus (SLE). Single-cell mitochondrial mass (SCMM), low mitochondrial membrane potential (MMP-Low) in lymphocytes, and circulating mitochondrial DNA (mtDNA) can reflect mitochondrial impairment and may serve as potential novel biomarkers for SLE. Purpose: We investigated the diagnostic utility of MMP-Low and SCMM in lymphocytes, as well as circulating mtDNA levels, in patients with SLE and examined their correlation with disease activity. Methods: Flow cytometry was performed to detect MMP-Low and SCMM in peripheral lymphocytes from patients with SLE (n = 52) and healthy controls (HCs, n = 30). The level of circulating mtDNA was quantified using PCR. Results: Patients with SLE exhibited significantly decreased MMP-Low in some peripheral lymphocyte subsets. Meanwhile, significantly increased SCMM in some lymphocyte subsets and circulating mtDNA were observed in patients with SLE. CD8 Conclusion: Our data showed that patients with SLE exhibit mitochondrial dysfunction. Several MMP-Low and SCMM in CD8+T cell subsets could serve as potential biomarkers for diagnosing SLE. Additionally, CD4

Indexed as

lymphocytesmitochondrial DNAmitochondrial massmitochondrial membrane potentialsystemic lupus erythematosus

Identifiers

PMID40548349
PMCPMC12178850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.